Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

485 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Humoral response to neurofilaments and dipeptide repeats in ALS progression.
Puentes F, Lombardi V, Lu CH, Yildiz O, Fratta P, Isaacs A, Bobeva Y, Wuu J; ALS Biomarker Consortium; CReATe Consortium; Benatar M, Malaspina A. Puentes F, et al. Among authors: yildiz o. Ann Clin Transl Neurol. 2021 Sep;8(9):1831-1844. doi: 10.1002/acn3.51428. Epub 2021 Jul 27. Ann Clin Transl Neurol. 2021. PMID: 34318620 Free PMC article.
Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain.
Thompson AG, Gray E, Verber N, Bobeva Y, Lombardi V, Shepheard SR, Yildiz O, Feneberg E, Farrimond L, Dharmadasa T, Gray P, Edmond EC, Scaber J, Gagliardi D, Kirby J, Jenkins TM, Fratta P, McDermott CJ, Manohar SG, Talbot K, Malaspina A, Shaw PJ, Turner MR. Thompson AG, et al. Among authors: yildiz o. Brain Commun. 2022 Feb 9;4(1):fcac029. doi: 10.1093/braincomms/fcac029. eCollection 2022. Brain Commun. 2022. PMID: 35224491 Free PMC article.
Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.
Mao Z, Álvarez-González C, Allen-Philbey K, De Trane S, Yildiz O, Campion T, Adams A, Turner BP, Marta M, Gnanapavan S, Espasandin M, Mathews J, Giovannoni G, Baker D, Schmierer K. Mao Z, et al. Among authors: yildiz o. Mult Scler Relat Disord. 2019 Jan;27:247-253. doi: 10.1016/j.msard.2018.11.001. Epub 2018 Nov 2. Mult Scler Relat Disord. 2019. PMID: 30419510
Severe skin reactions associated with cladribine in people with multiple sclerosis.
Mateo-Casas M, Reyes S, O'Toole EA, De Trane S, Yildiz O, Allen-Philbey K, Mathews J, Baker D, Giovannoni G, Schmierer K. Mateo-Casas M, et al. Among authors: yildiz o, o toole ea. Mult Scler Relat Disord. 2020 Aug;43:102140. doi: 10.1016/j.msard.2020.102140. Epub 2020 Apr 28. Mult Scler Relat Disord. 2020. PMID: 32454296
Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients.
Allen-Philbey K, De Trane S, Mao Z, Álvarez-González C, Mathews J, MacDougall A, Stennett A, Zhou X, Yildiz O, Adams A, Bianchi L, Blain C, Chapman C, Chung K, Constantinescu CS, Dalton C, Farrell RA, Fisniku L, Ford H, Gran B, Hobart J, Khaleeli Z, Mattoscio M, Pavitt S, Pearson O, Peruzzotti-Jametti L, Scalfari A, Sharrack B, Silber E, Tallantyre EC, Webb S, Turner BP, Marta M, Gnanapavan S, Juliusson G, Giovannoni G, Baker D, Schmierer K. Allen-Philbey K, et al. Among authors: yildiz o. Ther Adv Neurol Disord. 2021 Nov 25;14:17562864211057661. doi: 10.1177/17562864211057661. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 35173808 Free PMC article.
Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?
Mao Z, Álvarez-Gonzalez C, De Trane S, Yildiz O, Albor C, Doctor G, Soon D, Pepper G, Turner BP, Marta M, Mathews J, Giovannoni G, Baker D, Schmierer K. Mao Z, et al. Among authors: yildiz o. Mult Scler J Exp Transl Clin. 2018 Jun 26;4(2):2055217318783767. doi: 10.1177/2055217318783767. eCollection 2018 Apr-Jun. Mult Scler J Exp Transl Clin. 2018. PMID: 30090639 Free PMC article.
485 results